Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection

Through living-donor liver transplantation (LDLT) from a human leukocyte antigen (HLA)-matched sibling donor, it may be possible to stop the use of immunosuppressants. It is that acute antibody-mediated rejection and chronic active through positivity donor-specific anti-HLA antibodies and/or T cell-mediated affect prognosis transplantation. The etiologies diseases recipient also post-transplantation course. Herein, we report on successful re-treatment with direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection in patient who underwent LDLT HLA-matched donor. After for HCV-related diseases, easy HCV re-infect graft under lack DAA re-infection immediately after should commenced, important eradicate better recipients diseases.